(HealthDay)—Cimzia (certolizumab pegol) injection has been approved to treat adults with nonradiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation, the U.S. Food and Drug ...
May 27, 2009 — The US Food and Drug Administration (FDA) has approved risperidone long-acting injection for use alone or with lithium or valproate in the treatment of bipolar I disorder; and ...
A self-injection pen prefilled with Brussels-based UCB’s Cimzia (certolizumab pegol) has been made available this week in the U.K. after a positive opinion from the EMA. UCB developed the AutoClicks ...
* EMA has recommended the Cimzia dose dispenser cartridge for use with the re-usable ava electronic injection device in all approved indications Source text: bit.ly/2qcXlVg Further company coverage: ...
WASHINGTON The Food and Drug Administration today approved Cimzia, a new drug by UCB to treat Crohn’s disease. Crohn’s disease is a chronic, inflammatory bowel disease. It has no cure and its cause is ...
UCB's CIMZIA® (certolizumab pegol) approved by the U.S. FDA for adult patients suffering from moderate to severe rheumatoid arthritis Available this week, Cimzia® (certolizumab pegol), the only ...
UCB’s Cimzia (certolizumab pegol) is an effective treatment for patients with moderate to severe Crohn’s disease, according to Phase III data presented at this week’s United European Gastroenterology ...
Belgium's UCB has submitted a BLA to the FDA for Cimzia as a treatment for Crohn's disease. And the developer says it plans to file a European submission in a matter of weeks. If approved, Cimzia ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results